Tag Archives: National Hemophilia Foundation

June, 2018

November, 2015

  • 16 November

    FDA Approves Baxalta’s Adynovate for Treatment of Hemophilia A

    BANNOCKBURN, Ill.–(BUSINESS WIRE)– Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment …